OBJECTIVE: CD248 (tumor endothelial marker 1/endosialin) is found on stromal cells and is highly expressed during malignancy and inflammation. Studies have shown a reduction in inflammatory arthritis in CD248-knockout (CD248(-/-) ) mice. The aim of the present study was to investigate the functional effect of genetic deletion of CD248 on bone mass. METHODS: Western blotting, polymerase chain reaction, and immunofluorescence were used to investigate the expression of CD248 in humans and mice. Micro-computed tomography and the 3-point bending test were used to measure bone parameters and mechanical properties of the tibiae of 10-week-old wild-type (WT) or CD248(-/-) mice. Human and mouse primary osteoblasts were cultured in medium containing 10 mM β-glycerophosphate and 50 μg/ml ascorbic acid to induce mineralization, and then treated with platelet-derived growth factor BB (PDGF-BB). The mineral apposition rate in vivo was calculated by identifying newly formed bone via calcein labeling. RESULTS: Expression of CD248 was seen in human and mouse osteoblasts, but not osteoclasts. CD248(-/-) mouse tibiae had higher bone mass and superior mechanical properties (increased load required to cause fracture) compared to WT mice. Primary osteoblasts from CD248(-/-) mice induced increased mineralization in vitro and produced increased bone over 7 days in vivo. There was no decrease in bone mineralization and no increase in proliferation of osteoblasts in response to stimulation with PDGF-BB, which could be attributed to a defect in PDGF signal transduction in the CD248(-/-) mice. CONCLUSION: There is an unmet clinical need to address rheumatoid arthritis-associated bone loss. Genetic deletion of CD248 in mice results in high bone mass due to increased osteoblast-mediated bone formation, suggesting that targeting CD248 in rheumatoid arthritis may have the effect of increasing bone mass in addition to the previously reported effect of reducing inflammation.
OBJECTIVE: CD248 (tumor endothelial marker 1/endosialin) is found on stromal cells and is highly expressed during malignancy and inflammation. Studies have shown a reduction in inflammatory arthritis in CD248-knockout (CD248(-/-) ) mice. The aim of the present study was to investigate the functional effect of genetic deletion of CD248 on bone mass. METHODS: Western blotting, polymerase chain reaction, and immunofluorescence were used to investigate the expression of CD248 in humans and mice. Micro-computed tomography and the 3-point bending test were used to measure bone parameters and mechanical properties of the tibiae of 10-week-old wild-type (WT) or CD248(-/-) mice. Human and mouse primary osteoblasts were cultured in medium containing 10 mM β-glycerophosphate and 50 μg/ml ascorbic acid to induce mineralization, and then treated with platelet-derived growth factor BB (PDGF-BB). The mineral apposition rate in vivo was calculated by identifying newly formed bone via calcein labeling. RESULTS: Expression of CD248 was seen in human and mouse osteoblasts, but not osteoclasts. CD248(-/-) mouse tibiae had higher bone mass and superior mechanical properties (increased load required to cause fracture) compared to WT mice. Primary osteoblasts from CD248(-/-) mice induced increased mineralization in vitro and produced increased bone over 7 days in vivo. There was no decrease in bone mineralization and no increase in proliferation of osteoblasts in response to stimulation with PDGF-BB, which could be attributed to a defect in PDGF signal transduction in the CD248(-/-) mice. CONCLUSION: There is an unmet clinical need to address rheumatoid arthritis-associated bone loss. Genetic deletion of CD248 in mice results in high bone mass due to increased osteoblast-mediated bone formation, suggesting that targeting CD248 in rheumatoid arthritis may have the effect of increasing bone mass in addition to the previously reported effect of reducing inflammation.
Authors: Margarida Maia; Astrid de Vriese; Tom Janssens; Michaël Moons; Kristel van Landuyt; Jan Tavernier; Rik J Lories; Edward M Conway Journal: Arthritis Rheum Date: 2010-12
Authors: Brian Tomkowicz; Katherine Rybinski; Brian Foley; Wolfgang Ebel; Brad Kline; Eric Routhier; Philip Sass; Nicholas C Nicolaides; Luigi Grasso; Yuhong Zhou Journal: Proc Natl Acad Sci U S A Date: 2007-11-06 Impact factor: 11.205
Authors: Reinhard Gruber; Florian Karreth; Barbara Kandler; Gabor Fuerst; Antal Rot; Michael B Fischer; Georg Watzek Journal: Platelets Date: 2004-02 Impact factor: 3.862
Authors: Stuart W Smith; Kevin S Eardley; Adam P Croft; Joel Nwosu; Alexander J Howie; Paul Cockwell; Clare M Isacke; Christopher D Buckley; Caroline O S Savage Journal: Kidney Int Date: 2011-04-13 Impact factor: 10.612
Authors: Siân Lax; Debbie L Hardie; Amy Wilson; Mike R Douglas; Graham Anderson; David Huso; Clare M Isacke; Christopher D Buckley Journal: Eur J Immunol Date: 2010-07 Impact factor: 5.532
Authors: Maria Arantzazu Sanchez-Fernandez; Anne Gallois; Thilo Riedl; Pierre Jurdic; Bernard Hoflack Journal: PLoS One Date: 2008-10-27 Impact factor: 3.240
Authors: Piyushkumar R Kapopara; Nooshin S Safikhan; Jenny L Huang; Scott C Meixner; Kevin Gonzalez; Houra Loghmani; Wolfram Ruf; Alan E Mast; Victor Lei; Edward L G Pryzdial; Edward M Conway Journal: J Thromb Haemost Date: 2021-05-07 Impact factor: 16.036
Authors: Domokos Bartis; Louise E Crowley; Vijay K D'Souza; Lee Borthwick; Andrew J Fisher; Adam P Croft; Judit E Pongrácz; Richard Thompson; Gerald Langman; Christopher D Buckley; David R Thickett Journal: BMC Pulm Med Date: 2016-04-14 Impact factor: 3.317
Authors: Annika Wilhelm; Victoria Aldridge; Debashis Haldar; Amy J Naylor; Christopher J Weston; Ditte Hedegaard; Abhilok Garg; Janine Fear; Gary M Reynolds; Adam P Croft; Neil C Henderson; Christopher D Buckley; Philip N Newsome Journal: Gut Date: 2015-06-15 Impact factor: 23.059
Authors: Sahana Suresh Babu; Yanet Valdez; Andrea Xu; Alice M O'Byrne; Fernando Calvo; Victor Lei; Edward M Conway Journal: BMC Cancer Date: 2014-02-20 Impact factor: 4.430